Palvella Therapeutics, Inc.
PVLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.01 | -0.08 |
| FCF Yield | -40.58% | -63.57% | -93.83% | -62.77% |
| EV / EBITDA | 4.34 | 0.76 | 0.01 | 2.06 |
| Quality | ||||
| ROIC | -18.50% | -228.78% | -404.71% | -49.81% |
| Gross Margin | 0.00% | 0.00% | 89.27% | 92.46% |
| Cash Conversion Ratio | 0.62 | -0.73 | 0.54 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 2,958,669.27% | 3,155,336.99% |
| Free Cash Flow Growth | 20.89% | 7.66% | -72.38% | 82.29% |
| Safety | ||||
| Net Debt / EBITDA | 6.37 | -0.39 | 0.53 | 2.37 |
| Interest Coverage | -3.26 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -417.65 | -1,288.49 |